197 related articles for article (PubMed ID: 19421825)
1. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Vallböhmer D; Alakus H; Kütting F; Lurje G; Bollschweiler E; Wienand-Dorweiler A; Drebber U; Hölscher AH; Metzger R
J Gastrointest Surg; 2009 Aug; 13(8):1411-21. PubMed ID: 19421825
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
3. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
[TBL] [Abstract][Full Text] [Related]
4. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group.
Yoon HH; Catalano PJ; Murphy KM; Skaar TC; Philips S; Powell M; Montgomery EA; Hafez MJ; Offer SM; Liu G; Meltzer SJ; Wu X; Forastiere AA; Benson AB; Kleinberg LR; Gibson MK
BMC Cancer; 2011 May; 11():176. PubMed ID: 21586140
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus.
Brabender J; Vallböhmer D; Grimminger P; Hoffmann AC; Ling F; Lurje G; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
J Gastrointest Surg; 2008 Nov; 12(11):1815-21. PubMed ID: 18769985
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
8. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.
Chen WH; Xin PL; Pan QX; Chen YY; Wang CR; Zhang ZS; Chen YF; Zhang CY; Cai WJ
PLoS One; 2014; 9(9):e106600. PubMed ID: 25191856
[TBL] [Abstract][Full Text] [Related]
10. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
11. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
[TBL] [Abstract][Full Text] [Related]
12. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.
Yin Z; Zhou B; He Q; Li M; Guan P; Li X; Cui Z; Xue X; Su M; Ma R; Bai W; Xia S; Jiang Y; Xu S; Lv Y; Li X
BMC Cancer; 2009 Dec; 9():439. PubMed ID: 20003463
[TBL] [Abstract][Full Text] [Related]
13. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma.
Jin H; Xie X; Wang H; Hu J; Liu F; Liu Z; Zhou J; Zhang Y; Xi X; Hu B; Liao Y; Tang J
PLoS One; 2014; 9(7):e101256. PubMed ID: 25025378
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
16. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.
Han JY; Yoon KA; Park JH; Lee YJ; Lee GK; Han JH; Yoon SJ; Yun T; Kim HT; Lee JS
Cancer; 2011 Jul; 117(14):3201-8. PubMed ID: 21264830
[TBL] [Abstract][Full Text] [Related]
17. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
[TBL] [Abstract][Full Text] [Related]
18. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
[TBL] [Abstract][Full Text] [Related]
20. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]